LDN bei Krebs (Forum)

GabiK, Freitag, 21. Dezember 2007, 15:29 (vor 3953 Tagen) @ GabiK

Das sind die einzigen zwei e-mails von Dr. Gluck zum Thema Krebs. Es geht um diese Krebs/LDN Konferenz. Ich bin sicher das ist auch auf der LDN Webseite zu lesen.

sender: Joel Gluck <joelgluck@yahoo.com>
Date: Tuesday, April 24, 2007 10:52

On the afternoon of April 20th, at its offices in Rockville, Maryland, the National Cancer
Institute (part of the US government's National Institutes of Health, or NIH) held a
conference entitled "Low Dose Opioid Blockers, Endorphins, and Metenkephalin: Promising
Compounds for Unmet Medical Needs."

Following welcoming remarks from Jeffrey Abrams, MD, Chief of the Clinical Investigations
Branch of the NCI, speakers included David Gluck, MD (Introductory Overview); Jill Smith,
MD (Clinical Experience with LDN in Crohn's Disease; Opioid Growth Factor in Pancreatic
Cancer); John Hong, PhD (Anti-Inflammatory and Neuroprotective Effects of Naltrexone
and Its Analogs); Nicholas Plotnikoff, PhD (Overview of Metenkephalin Actions in HIV Infections); Burton M. Berkson, MD, PhD (Personal Experiences with LDN for Various
Cancers); Maira Gironi, MD, PhD and Filippo M. Boneschi, MD, PhD (Ongoing Pilot Study of
LDN in MS: Preliminary Findings). Dr. Abrams then delivered the concluding remarks and
announced his intention to prepare a written summary of the entire meeting. Once that
becomes available, we intend to present it as a linked page to the LDN website.

LDN Website Editors

LDN Website Update - May 11, 2007
www.lowdosenaltrexone.org / www.ldninfo.org

Latest News As of May 2007 (Updated):

LDN's Effectiveness Highlighted in New Presentations

We have received permission to display the following two complete slide presentations,
which portray the important therapeutic effects of LDN in a broad array of challenging
human illnesses:

1) Dr. Burton Berkson, MD, PhD, a clinician from Las Cruces, New Mexico, contributed a
copy of his presentation from the April 2007 meeting hosted by the National Cancer
Institute. The slides include multiple images of CT scans and PET scans that document
unprecedented remissions in heretofore terminally ill patients.

2) Niles Bauer, PhD candidate, Department of Microbiology and Immunology, College of
Medicine, University of Arizona, supplied a copy of a presentation to his department in
March 2007. He observed "profound" improvements within a month after the start of LDN
treatment in people with a wide variety of autoimmune disorders.

(Please visit http://www.lowdosenaltrexone.org/ldn_latest_news.htm to view these
presentations -- click on the underlined "presentation" links. Presentations are in PDF
format and are large -- may take several minutes to display. Corresponding changes/
updates have also been made to the linked page "What Others Are Saying About LDN.")

LDN Website Editors

gesamter Thread:

 RSS-Feed dieser Diskussion

powered by my little forum